Using 3D imaging to assess pancreatic cancer prognosis
Official title: 3D-MRE-Based Evaluation of Biomechanical Heterogeneity in Pancreatic Cancer and Its Clinical Prognosis
Run by Shengjing Hospital · NCT06849063 · Data updated 2026-11-12
This study is testing if advanced 3D imaging can help doctors better understand the outlook for patients with pancreatic cancer by looking at the stiffness of the tissue around the tumor.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | October 9, 2020 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT06849063 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with confirmed pancreatic ductal adenocarcinoma and no history of other malignancies.
✕Probably not a fit
Patients with very small tumors (less than 1.0 cm) or those who cannot undergo the imaging procedure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) by utilizing advanced three-dimensional magnetic resonance elastography (3D-MRE). The study focuses on the biomechanical properties of the extracellular matrix surrounding PDAC, which are linked to tumor behavior and patient survival. By noninvasively measuring tissue stiffness, the research seeks to identify potential prognostic biomarkers that could guide treatment decisions and improve patient outcomes. The study will include patients with confirmed PDAC and will analyze their imaging data over a specified follow-up period.
Why it matters
Potential benefit: If successful, this study could provide a novel noninvasive method for predicting survival in pancreatic cancer patients, leading to more personalized treatment strategies.
How similar studies have gone: While the use of MRE in other contexts has shown promise, this specific application for predicting PDAC prognosis is novel and has not been systematically explored in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. granting of written informed consent 2. age ≥18 years 3. no history of extrapancreatic malignancy 4. no preoperative biliary drainage 5. definitive histologic evidence of PDAC in excisional biopsy 6. with no less than three months of postoperative mortality or six months of follow- up Exclusion Criteria: 1. inability to re-review of tissue specimens 2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection 3. tumor diameters \<1.0 cm 4. withdrawal/dropout during follow-up
Where it's running
-
Shengjing hospital of China medical university
Shenyang, Liaoning, China Recruiting
Study contacts
- Principal investigator: Yu Shi, MD.PhD. — Study Principal Investigator
- Study coordinator: Yu Shi, MD.PhD.
- Email: 18940259980@163.com
- Phone: 18940259980
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.